Replies to post #12337 on Cel Sci Corporation (CVM)

[lux1]

At Clinicaltrial they don't say 10% of OS improvement but only the more usual P-Value between the 2 group less than 0.05.
Not a little difference.

Primary Outcome Measures:
Overall Survival (OS) in LI + CIZ + SOC vs. SOC [ Time Frame: 3 year ]
OS will be assessed using Kaplan-Meier life-table and compared using a logrank test and confirmed further with tumor stage location and geographic stratified log rank tests. The unstratified logrank test constitutes the primary analysis. A two-sided p-value of 0.05 or less will be considered statistically significant for comparing the two groups. Interim analyses will be performed throughout the study to assess safety, sample size and futility.